Stuart Rich - 09 Jan 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Chief Medical Officer, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
4
Filing time
13 Jan 2026, 21:14:07 UTC
Previous filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rich Stuart Chief Medical Officer, Director 101 GLEN LENNOX DRIVE SUITE 300, CHAPEL HILL /s/ S. Halle Vakani, as Attorney-in-Fact 13 Jan 2026 0001841785

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TENX Common Stock 5,266 09 Jan 2026 Direct
holding TENX Common Stock 1,194 09 Jan 2026 By Stuart Rich 2022 Irrevocable Trust F1
holding TENX Common Stock 1,194 09 Jan 2026 By Andrea Rich 2021 Irrevocable Trust F2
holding TENX Common Stock 5,000 09 Jan 2026 By Stuart Rich Revocable Trust DTD 11/18/1996 F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +250,000 $0.000000 250,000 09 Jan 2026 Common Stock 250,000 $13.30 Direct F4
holding TENX Stock Option (right to buy) 157 09 Jan 2026 Common Stock 157 $2848.00 Direct F5
holding TENX Stock Option (right to buy) 63 09 Jan 2026 Common Stock 63 $992.00 Direct F6
holding TENX Stock Option (right to buy) 119 09 Jan 2026 Common Stock 119 $3.55 Direct F7
holding TENX Stock Option (right to buy) 500,000 09 Jan 2026 Common Stock 500,000 $5.94 Direct
holding TENX Stock Option (right to buy) 625,000 09 Jan 2026 Common Stock 625,000 $5.89 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F2 The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
F5 The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment.
F6 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F7 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
F8 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.